Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]NOTA-ABY030 PET/CT in Head and Neck Squamous Cell Carcinoma
NCT07217028Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Apr 2026
- Primary completion
- Apr 2029
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]NOTA-ABY030 in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Adverse Events at 7 days. Started Apr 2026; status: recruiting.
02
Drugs
[18F]NOTA-ABY030
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07217028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217028.